G1 Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Okay. Let's get started here. Welcome, everybody, to the Wednesday afternoon of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Malcolm Kuno and Priyanka Grover from the team. I will start out the afternoon session with a presentation from G1 Therapeutics, and presenting on behalf of the company, we have CEO, Jack Bailey. Jack?
Thank you, Anupam. It is great to be here live this year at JPMorgan Healthcare Conference. So G1's mission statement is about improving the lives of those impacted by cancer. And since the approval of our first product, COSELA, chemical name trilaciclib, in 2021, we have been intensely focused on fulfilling that mission, both by commercializing it for our initial indication in extensive stage small cell lung cancer, but also executing on 5 clinical studies to expand its use both in different types of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
